Search Results

VALPROIC ACID AS A TREATMENT FOR RETINITIS PIGMENTOSA

Clinical trials of valproic acid for the treatment of retinitis pigmentosa began in both the USA and Korea in late 2011. As well, a smaller shorter open-label trial was begun in Japan....

EYELEA APPROVED TO TREAT WET AMD IN CANADA

An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc....

VALPROIC ACID: THE PERILS OF USING DRUGS OFF-LABEL

Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa...

SPOTLIGHT ON SIGHT

YOUR DOLLARS AT WORK

RARE DISEASE DAY: AN UPDATE ON INHERITED RETINAL DISEASE RESEARCH

February 28 is Rare Disease Day. In recognition of the day, Fighting Blindness Canada is raising awareness to drive change for those with rare diseases, including an inherited retinal disease (IRD). New...